Q-omics provides the consensus-scored LRRC59 profile across patient tissues and cancer cell-line models. LRRC59 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LRRC59 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, LRRC59 protein abundance shows 22,011 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, HNSC, and GBM as cancer lineages where LRRC59 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC59 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC59 survival associations across molecular data types. LRRC59 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC59 RNA expression–survival associations across cancer types. High LRRC59 expression shows unfavorable associations in KIRP, HNSC, UVM, ACC, BLCA and MESO. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LRRC59 RNA expression.
This table summarizes LRRC59 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for LRRC59. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC59 shows higher tumor expression in HNSC, KIRC, BLCA, KIRP, LIHC and LUAD. The HNSC box plot shows higher LRRC59 RNA expression in tumor versus normal tissue (log2 FC = +1.192, t-test p < 0.001).
This table shows molecular features associated with LRRC59 in patient tissues and cancer cell lines. In patient samples, LRRC59 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC59 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
